Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $5 to $4.
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $5 to $4.